Related Experiment Videos
Cardiac morphologic and functional changes induced by epirubicin chemotherapy
M D Dardir1, V J Ferrans, Y S Mikhael
1Ultrastructure Section, National Heart, Lung and Blood Institute, Bethesda, MD.
Summary
Epirubicin chemotherapy can cause cardiac toxicity, with significant heart damage risk increasing above 450 mg/m2. Monitoring is crucial for patients receiving high epirubicin doses to manage potential heart issues.
Area of Science:
- Oncology
- Cardiology
- Pharmacology
Background:
- Epirubicin is a common chemotherapeutic agent.
- Cardiac toxicity is a known side effect of anthracycline chemotherapy.
Purpose of the Study:
- To evaluate cardiac toxicity in patients receiving epirubicin.
- To determine a safe dosage threshold for epirubicin to mitigate cardiac damage.
Main Methods:
- 24 patients received epirubicin as a single agent at different doses.
- Echocardiography and endomyocardial biopsies were used to assess cardiac function and pathology.
- Correlation between epirubicin dose and cardiac damage was analyzed using the Billingham scale.
Main Results:
- No overt heart failure or significant arrhythmias were observed.
- A strong correlation (r = .7, P = .0006) was found between epirubicin dose and cardiac pathologic changes.
- A statistically defined cut-off point for increased cardiac damage was identified at 450 mg/m2.
Conclusions:
- Epirubicin doses exceeding 450 mg/m2 are associated with a higher probability of cardiac damage.
- Patients receiving epirubicin above 450 mg/m2 require cardiac toxicity monitoring.
- Continuation of therapy beyond 900 mg/m2 should be guided by monitoring results.